BOOK
Early-Stage Breast Cancer: New Developments and Controversies, An Issue of Surgical Oncology Clinics - E- Book
(2010)
Additional Information
Book Details
Abstract
This issue of the Surgical Oncology Clinics will focus on new advances in Breast Cancer Surgery, and will include articles on Chemoprevention, Breast MRI, Genomics, Sentinel Node Biopsy, Extra-axillary Sentinel Nodes, Skin-Sparing and Nipple Sparing Mastectomy, Oncoplastic Techniques, Neoadjuvant Hormonal Therapy, Neoadjuvant Chemotherapy, Adjuvant Hormonal Therapy, Adjuvant Chemotherapy, and Biologic Targeted Therapies.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Contributors | iii | ||
| Contents | vii | ||
| FORTHCOMING ISSUES | xii | ||
| RECENT ISSUES | xii | ||
| Foreword | xiii | ||
| Preface | xv | ||
| Erratum | xvii | ||
| Chapter 1. Breast Cancer Chemoprevention: Progress and Controversy | 463 | ||
| SELECTED ESTROGEN RECEPTOR MODULATORS | 464 | ||
| TAMOXIFEN CHEMOPREVENTION TRIALS | 464 | ||
| ADDITIONAL TAMOXIFEN BREAST CANCER PREVENTION TRIALS | 466 | ||
| RALOXIFENE STUDIES | 466 | ||
| THE STUDY OF TAMOXIFEN AND RALOXIFENE TRIAL, NSABP P-2 | 468 | ||
| ADDITIONAL SERMS | 470 | ||
| AROMATASE INHIBITORS | 470 | ||
| 2009 AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINES ON THE USE OF PHARMACOLOGIC INTERVENTION, INCLUDING TAMOXIFEN, RALOXIFENE, AND AIS, FOR BREAST CANCER RISK REDUCTION | 471 | ||
| SUMMARY | 471 | ||
| REFERENCES | 472 | ||
| Chapter 2. Magnetic Resonance Imaging for Screening, Diagnosis, and Eligibility for Breast-conserving Surgery: Promises and Pitfalls | 475 | ||
| MRI FOR SCREENING | 476 | ||
| MRI FOR TREATMENT SELECTION | 479 | ||
| MRI FOR DETECTION OF LOCAL RECURRENCE | 486 | ||
| SUMMARY | 487 | ||
| REFERENCES | 487 | ||
| Chapter 3. Clinical Significance of Minimal Sentinel Node Involvement and Management Options | 493 | ||
| WHAT CONSTITUTES A POSITIVE SENTINEL LYMPH NODE? | 493 | ||
| TREATMENT OF SENTINEL NODE POSITIVE DISEASE: THE NEED FOR ALND? | 496 | ||
| PREDICTIVE MODELS | 497 | ||
| CLINICAL TRIALS | 499 | ||
| SUMMARY | 500 | ||
| REFERENCES | 500 | ||
| Chapter 4. Clinical Significance and Management of Extra-Axillary Sentinel Lymph Nodes: Worthwhile or Irrelevant? | 507 | ||
| INTERNAL MAMMARY SLNs | 507 | ||
| OTHER SITES OF NONAXILLARY SLN | 513 | ||
| SUMMARY | 514 | ||
| REFERENCES | 514 | ||
| Chapter 5. Sentinel Lymph Node Biopsy Before or After Neoadjuvant Chemotherapy: Pros and Cons | 519 | ||
| POTENTIAL ADVANTAGES TO SLN BIOPSY BEFORE NEOADJUVANT CHEMOTHERAPY | 520 | ||
| POTENTIAL ADVANTAGES TO SLN BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY | 522 | ||
| MUST A POSITIVE PRETREATMENT SLN BIOPSY COMMIT A PATIENT TO AN ALND AFTER CHEMOTHERAPY? | 524 | ||
| IS SLN BIOPSY ACCURATE AFTER NEOADJUVANT CHEMOTHERAPY? | 524 | ||
| ACCURACY IN THE FACE OF CLINICALLY INVOLVED NODES BEFORE CHEMOTHERAPY | 525 | ||
| ACCURACY IN THE FACE OF CLINICALLY NEGATIVE NODES | 526 | ||
| IS IT SAFE TO AVOID ALND AFTER A NEGATIVE SLN BIOPSY FOLLOWING NEOADJUVANT CHEMOTHERAPY? | 527 | ||
| WHICH APPROACH PROVIDES THE MOST RELEVANT PROGNOSTIC/PREDICTIVE INFORMATION? | 529 | ||
| MUST ONE APPROACH BE UNIVERSALLY APPLIED? | 531 | ||
| REFERENCES | 532 | ||
| Chapter 6. Sentinel Lymph Node Surgery in Uncommon Clinical Circumstances | 539 | ||
| BREAST CANCER IN MEN | 539 | ||
| PREGNANT PATIENTS WITH BREAST CANCER | 540 | ||
| DUCTAL CARCINOMA IN SITU | 541 | ||
| MULTICENTRIC/MULTIFOCAL BREAST CANCER | 542 | ||
| NEOADJUVANT CHEMOTHERAPY | 542 | ||
| PREVIOUS BREAST SURGERY | 543 | ||
| PREVIOUS AXILLARY SURGERY | 544 | ||
| INTERNAL MAMMARY SLN SURGERY | 545 | ||
| PROPHYLACTIC MASTECTOMY | 546 | ||
| SUMMARY | 547 | ||
| REFERENCES | 547 | ||
| Chapter 7. Total Skin Sparing (Nipple Sparing) Mastectomy: What is the Evidence? | 555 | ||
| LITERATURE REVIEW | 556 | ||
| TECHNICAL CONSIDERATIONS | 558 | ||
| PATIENT SELECTION FOR TOTAL SKIN SPARING MASTECTOMY | 559 | ||
| TECHNICAL APPROACHES: INCISION PLANNING | 559 | ||
| TECHNICAL CONSIDERATIONS: CREATING SKIN FLAPS | 559 | ||
| DISCUSSION | 560 | ||
| REFERENCES | 565 | ||
| Chapter 8. Oncoplastic Surgery: A Creative Approach to Breast Cancer Management | 567 | ||
| HISTORICAL PERSPECTIVE | 567 | ||
| DEFINITION OF ONCOPLASTIC SURGERY | 570 | ||
| ONCOPLASTIC SURGERY AND BREAST CANCER | 570 | ||
| PREOPERATIVE ASSESSMENT | 573 | ||
| SURGICAL PLANNING | 574 | ||
| THE SMALL BREAST | 575 | ||
| THE LARGE BREAST | 575 | ||
| SUMMARY | 578 | ||
| REFERENCES | 579 | ||
| Chapter 9. Clinical Application of Gene Expression Profiling in Breast Cancer | 581 | ||
| PROGNOSTIC AND PREDICTIVE MARKERS | 584 | ||
| PROCESS FOR DEVELOPMENT OF A MULTIPARAMETER ASSAY | 585 | ||
| METHODS FOR ANALYZING GENE EXPRESSION | 585 | ||
| QUALITY CONTROL OF GENE EXPRESSION ANALYSIS METHODS | 588 | ||
| METHODS FOR BIOINFORMATICS ANALYSIS OF GENE EXPRESSION | 589 | ||
| VALIDITY, REPRODUCIBILITY, AND REPORTING OF MICROARRAY STUDIES | 590 | ||
| REGULATORY APPROVAL OF MULTIPARAMETER ASSAYS | 591 | ||
| CLASSIFIERS DEVELOPED BY SUPERVISED ANALYSIS | 591 | ||
| MULTIPARAMETER ASSAYS COMPARED WITH INTEGRATED CLINICAL INFORMATION | 597 | ||
| CLASSIFIERS DEVELOPED BY OTHER METHODS | 597 | ||
| WOUND-RESPONSE SIGNATURE | 599 | ||
| INVASIVE GENE SIGNATURE | 599 | ||
| PROSPECTIVE CLINICAL TRIALS EVALUATING MULTIPARAMETER ASSAYS | 600 | ||
| CLINICAL USEFULNESS OF MULTIPARAMETER ASSAYS AND CONCLUSIONS | 600 | ||
| REFERENCES | 602 | ||
| Chapter 10. Neoadjuvant Chemotherapy for Operable Breast Cancer: Individualizing Locoregional and Systemic Therapy | 607 | ||
| POTENTIAL BENEFITS OF NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER | 607 | ||
| PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY | 609 | ||
| CHEMOTHERAPY VERSUS HORMONAL THERAPY | 611 | ||
| PRE-THERAPY ASSESSMENT AND STAGING | 612 | ||
| OPTIMAL CHEMOTHERAPY REGIMEN | 613 | ||
| ASSESSING RESPONSE TO NEOADJUVANT CHEMOTHERAPY | 614 | ||
| RESECTION OF THE PRIMARY TUMOR: BREAST CONSERVATION VERSUS MASTECTOMY | 616 | ||
| MANAGEMENT OF REGIONAL LYMPH NODES IN PATIENTS TREATED WITH NCT | 617 | ||
| POSTMASTECTOMY REGIONAL/CHEST WALL IRRADIATION AFTER NEOADJUVANT CHEMOTHERAPY | 618 | ||
| SUMMARY | 619 | ||
| REFERENCES | 619 | ||
| Chapter 11. Neoadjuvant Endocrine Therapy for Breast Cancer | 627 | ||
| TAMOXIFEN VERSUS SURGERY | 627 | ||
| AIS VERSUS TAMOXIFEN | 628 | ||
| NEOADJUVANT CHEMOTHERAPY VERSUS ENDOCRINE THERAPY | 629 | ||
| BIOMARKER EVALUATION IN THE NEOADJUVANT ENDOCRINE SETTING TO PREDICT LONG-TERM OUTCOME | 630 | ||
| RECEPTOR, HER2 STATUS AND SENSITIVITY TO ENDOCRINE THERAPY | 631 | ||
| WHICH AI IS SUPERIOR? | 633 | ||
| PATIENT SELECTION FOR NEOADJUVANT CHEMOTHERAPY | 634 | ||
| NEW COMBINATIONS WITH ENDOCRINE THERAPY IN THE NEOADJUVANT SETTING | 635 | ||
| SUMMARY | 635 | ||
| REFERENCES | 636 | ||
| Chapter 12. Adjuvant Hormonal Therapy for Early-Stage Breast Cancer | 639 | ||
| TAMOXIFEN | 640 | ||
| ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR–POSITIVE EARLY-STAGE BREAST CANCER | 641 | ||
| ADJUVANT ENDOCRINE THERAPY FOR PREMENOPAUSAL WOMEN WITH HORMONE RECEPTOR–POSITIVE EARLY-STAGE BREAST CANCER | 644 | ||
| SUMMARY | 644 | ||
| REFERENCES | 645 | ||
| Chapter 13. Adjuvant Chemotherapy in Early-Stage Breast Cancer: What, When, and for Whom? | 649 | ||
| WHO SHOULD BE CONSIDERED FOR ADJUVANT CHEMOTHERAPY? | 651 | ||
| WHAT ADJUVANT CHEMOTHERAPY? | 653 | ||
| TUMOR BIOLOGY AND CHOICE OF ADJUVANT CHEMOTHERAPY | 658 | ||
| ADJUVANT CHEMOTHERAPY WHEN? | 661 | ||
| SUMMARY | 662 | ||
| REFERENCES | 662 | ||
| Chapter 14. Targeted Therapies in Early-Stage Breast Cancer: Achievements and Promises | 669 | ||
| WHAT IS MEANT BY TARGETED THERAPY? | 669 | ||
| TARGETED THERAPY IN THE CONTEXT OF GENOMICS | 670 | ||
| HER2-TARGETED THERAPY | 671 | ||
| NOVEL APPROACHES: ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY | 672 | ||
| NOVEL APPROACHES: CHEMOTHERAPY AS TARGETED THERAPY | 674 | ||
| NOVEL APPROACHES: PARP INHIBITION FOR TRIPLE-NEGATIVE (BASAL) BREAST CANCER | 674 | ||
| NOVEL APPROACHES: TARGETING SITE-SPECIFIC BONE METASTASIS | 675 | ||
| SUMMARY | 676 | ||
| REFERENCES | 677 | ||
| Index | 681 |